Vilon is one of the smallest peptides anyone has bothered to study for biological activity: just two amino acids, lysine joined to glutamic acid (Lys-Glu). You'll also see it written as L-lysyl-L-glutamic acid or lysylglutamic acid, CAS 45234-02-4. PubChem lists the molecular formula as C11H21N3O5.
It belongs to the family of peptide bioregulators associated with Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology. The idea behind that program was to take short peptide fragments said to mimic signals from specific tissues, in Vilon's case the thymus, and test them as regulators of aging and immune function. That origin story matters for reading the evidence, because most of the published work on Vilon comes from this one research lineage.
What the research actually shows
The real literature on Vilon is preclinical: animal studies and cell cultures, not human clinical trials. A few specific findings are worth stating plainly because they cut in different directions.
Aging biomarkers in mice. In a study of female CBA mice, Anisimov, Khavinson and colleagues injected Lys-Glu monthly from 6 months of age. The dipeptide increased the animals' physical activity and was followed by a lower incidence of spontaneous lung adenomas, but it did not significantly extend mean or maximum lifespan, and the pineal peptide tested alongside it looked more promising on aging measures (Anisimov et al., *Mech Ageing Dev*, 2001).
A cautionary result. In FVB/N HER-2/neu transgenic mice, which are bred to develop mammary tumors, Vilon did the opposite of what you'd hope. Compared with controls, it was linked to a higher incidence of mammary cancer, a shorter latent period before tumors appeared, and a larger cumulative tumor count (Anisimov et al., *Int J Cancer*, 2002). The same peptide that looked protective in one model looked harmful in another. That is a real, published signal, not a footnote.
Cell-level effects. More recent in vitro work reported that Vilon, applied to lymphocytes from people aged 75 to 88, triggered "deheterochromatinization" (loosening) of certain condensed chromatin regions while leaving structural pericentromeric heterochromatin alone. The authors framed this as selective reactivation of silenced gene regions in old cells (Lezhava et al., *Georgian Med News*, 2023). This is a mechanistic observation in cultured cells, not evidence of a clinical benefit.
So the honest summary: there are genuine peer-reviewed studies, they are small, animal- and cell-based, largely from one group, and they include at least one result pointing the wrong way.
Regulatory and quality status
Vilon is not an approved drug in the United States. The FDA, EMA and similar agencies have not cleared it for any human use. It is sold as a research chemical and is not approved for human consumption. We're not aware of it appearing on the WADA Prohibited List by name; absence from that list is not a safety endorsement.
Because it ships as a research-only material from many vendors, the practical questions for a buyer are about what's actually in the vial, not clinical claims:
- Is there a recent certificate of analysis (COA) tied to that batch?
- Does an independent lab confirm identity (that it is Lys-Glu) and purity by HPLC and mass spec?
- Does the third-party result match the label?
Those are the points peptideone.org tracks and aggregates across vendors. A peptide this simple is cheap to make, which is exactly why independent verification of identity and purity is the thing worth checking before anything else.
Nothing here is medical or dosing advice. This is a neutral summary of public information, and the published human evidence for Vilon remains thin.